Igenomix
Belén Arnau Colomer is an experienced professional in quality assurance and regulatory affairs, currently serving as the Quality Assurance and Regulatory Affairs Director at Igenomix since July 2013. In this role, Belén manages the quality management system and oversees regulatory submissions for In-Vitro Diagnostic Medical Devices, while also serving as a key liaison with health authorities. Belén has a diverse background, having held various positions within Igenomix, including Quality and Internal Process Manager, Change Management Manager, and Quality Manager. Prior to Igenomix, Belén worked at ISOFOTON S.A. as Lead Manager and at Siliken S.A. as a Customer Service Specialist and Lead Manager. Educational qualifications include an Executive MBA from INEDE and a Master's Degree in Foreign Trade and International Relations from IMAFE, along with a degree in Tourism from the University of Valencia.
This person is not in any teams
Igenomix
Igenomix is a medical testing laboratory specializing in reproductive genetic services. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive. In 2021, Vitrolife acquired Igenomix, a leader in reproductive genetic testing services for IVF clinics, founded in 2011. Together we create Vitrolife Group, a global leader in reproductive health. By combining Igenomix’s portfolio of reproductive genetic testing services with Vitrolife’s best-in-class IVF device portfolio, we support clinics and patients across the fertility journey. Based on science and advanced research capabilities, our aim is to deliver products and services for the entire fertility journey, providing consistent performance and guaranteed quality. We are a sustainable market leader and aim to be the preferred partner to the fertility clinics by providing superior products and services. Currently, Vitrolife Group are approximately 1,100 people worldwide headquartered in Gothenburg, Sweden. Our products and services are available in more than 110 countries, through our own presence in 32 countries, and a network of distributors. Our vision is to enable people to fulfill the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. Together we create excellence in reproductive health. The Vitrolife AB (publ) share is listed on Nasdaq Stockholm.